Phase ΙΙ study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation.

Authors

Shintaro Kanda

Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

Shintaro Kanda , Yuichiro Ohe , Hidehito Horinouchi , Yutaka Fujiwara , Hiroshi Nokihara , Noboru Yamamoto , Ikuo Sekine , Hideo Kunitoh , Kaoru Kubota , Tomohide Tamura

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR).

First Author: Hiroshige Yoshioka

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

First Author: G. Lopes

insert_chart_outlined

Poster

2024 ASCO Annual Meeting

bookmark_border

REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.

First Author: Helena Alexandra Yu

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).

First Author: Atsushi Nakamura